The Journal of dermatological treatment · 2025
The efficacy of narrowband ultraviolet B phototherapy combination with tofacitinib in the treatment of vitiligo: a randomized controlled trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guo Xiaoyan, Zhang Dongxu, Chen Guangxiong, Xie Yijie, Mao Yibin
Аннотация
BACKGROUND: This randomized control clinical trial aimed to evaluate the efficacy of tofacitinib combined with phototherapy narrowband ultraviolet B (UVB) in the treatment of vitiligo.
METHODS: A total of 136 vitiligo patients were randomized to UVB treatment (UVB group) or UVB treatment combined with tofacitinib (TOF-UVB group). The patients were followed up for 24 weeks. In post-treatment analysis of treatment outcomes, the vitiligo area severity index (VASI) and dermatology life quality index (DLQI) were measured. Serum levels of inflammatory factors including IL-17, IL-23, IFN-γ and IL-6, were measured with enzyme-linked immunosorbent assay.
RESULTS: In post-treatment analysis, significantly more patients in the TOF-UVB group (n = 63) showed effective recovery compared to the UVB group (n = 61). TOF-UVB group also demonstrated markedly lower VASI and DLQI scores than the UVB group. Pronouncedly lower levels of inflammatory factors were also observed.
CONCLUSIONS: Our data suggest that UVB-TOF is potentially more effective than UVB alone in promoting recovery of vitiligo patients and reducing inflammatory factors.
METHODS: A total of 136 vitiligo patients were randomized to UVB treatment (UVB group) or UVB treatment combined with tofacitinib (TOF-UVB group). The patients were followed up for 24 weeks. In post-treatment analysis of treatment outcomes, the vitiligo area severity index (VASI) and dermatology life quality index (DLQI) were measured. Serum levels of inflammatory factors including IL-17, IL-23, IFN-γ and IL-6, were measured with enzyme-linked immunosorbent assay.
RESULTS: In post-treatment analysis, significantly more patients in the TOF-UVB group (n = 63) showed effective recovery compared to the UVB group (n = 61). TOF-UVB group also demonstrated markedly lower VASI and DLQI scores than the UVB group. Pronouncedly lower levels of inflammatory factors were also observed.
CONCLUSIONS: Our data suggest that UVB-TOF is potentially more effective than UVB alone in promoting recovery of vitiligo patients and reducing inflammatory factors.